Not all patients carrying BRCA1-deficient breast cancer responded equally well; some patients experienced relevant side effects from PARP inhibitors, including myelosuppression, gastrointestinal toxicity, hypercholesterolemia, fatigue, and teratogenicity [200,201]. This evidence concerns the gene BRCA1 and breast cancer.